Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Summit Therapeutics Inc.
The company signed a major contract or deal. An 8-K is the notice a US public company must file within four business days of a major event.
www.smmttx.comAI Executive Summary
AI-powered analysis of 8-K filing content
Summit Therapeutics Inc. raised $2.0 billion in gross proceeds through a private placement of Class A Convertible Preferred Stock with AstraZeneca Holdings B.V. on September 28, 2026. This substantial capital influx significantly strengthens the company's financial position for growth and strategic initiatives.
Key Takeaways
Summit issued 108,955.3686 shares of newly designated Class A Convertible Preferred Stock at $18,356.14 per share to AstraZeneca
Each preferred share is convertible into 1,000 shares of common stock at $0.01 par value, providing conversion optionality
2 more takeaways
Filing Overview
What This Means
Summit Therapeutics Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.